Table 5.

Summary of susceptibility profiles of aerobic bacteria

All gram-positive aerobes including Enterococcus spp.
Antibiotics	Susceptible (%)	Intermediate (%)	Resistant (%)	Total:
Ampicillin	21 (44.7)	0 (0)	26 (55.3)	47
Amox/Clav.	21 (44.7)	0 (0)	26 (55.3)	47
Pip/Taz.	21 (47.7)	0 (0)	23 (52.3)	44
Cefuroxime	12 (19.0)	0 (0)	51 (81.0)a	63
Cefotaxime	10 (20.4)	0 (0)	39 (79.6)a	49
Gentamycin	27 (51.9)	0 (0)	25 (48.1)	52
Tigecycline	42 (100)	0 (0)	0 (0)	42
Levofloxacin	21 (35.0)	2 (3.3)	37 (61.7)	60
Vancomycin	43 (76.8)	0 (0)	13 (23.2)	56
Imipenem	13 (34.2)	0 (0)	25 (65.8)	38
Linezolid	44 (97.8)	1 (2.2)	0 (0)	45
Enterococcus spp. only
Antibiotics	Susceptible (%)	Intermediate (%)	Resistant (%)	Total:
Ampicillin	12 (31.6)	0 (0)	26 (68.4)	38
Erythromycin	9 (25.0)	3 (8.3)	24 (66.7)	36
Imipenem	13 (34.2)	0 (0)	25 (65.8)	38
Tigecycline	32 (100)	0 (0)	0 (0)	32
Vancomycin	21 (60.0)	0 (0)	14 (40.0)	35
Teicoplanin	35 (92.1)	1 (2.6)	2 (5.3)	38
Levofloxacin	10 (26.3)	1 (2.6)	27 (71.1)	38
Linezolid	33 (97.1)	1 (2.9)	0 (0)	34
Daptomycin	7 (87.5)	0 (0)	1 (12.5)	8
All gram-negative aerobes
Antibiotics	Susceptible (%)	Intermediate (%)	Resistant (%)	Total:
Ampicillin	8 (15.1)	1 (1.9)	44 (83.0)	53
Amox/Clav	17 (33.3)	5 (9.8)	29 (56.9)	51
Pip/Taz	30 (52.6)	6 (10.5)	21 (36.8)	57
Cefuroxime	17 (33.3)	8 (15.7)	26 (51.0)	51
Cefotaxime	30 (60.0)	0 (0)	20 (40.0)	50
Ceftazidim	10 (66.7) (52.2)	2 (13.3)	3 (20.0)	15
Imipenem	53 (84.1)	3 (4.8)	7 11.1)	63
Meropenem	55 (90.2)	1 (1.6)	5 (8.2)	61
Gentamicin	52 (83.9)	0 (0)	10 (16.1)	62
Tigecycline	35 (71.4)	4 (8.2)	10 (20.4)	49
TMP/SMX	42 (73.7)	0 (0)	15 (26.3)	57
Levofloxacin	42 (68.9)	2 (3.3)	17 (27.9)	61
Ciprofloxacin	41 (68.3)	1 (1.7)	18 (30.0)	60

Amox/Clav amoxicillin/clavulanic acid, Pip/Taz piperacillin/tazobactam, TMP/SMX trimethoprim/sulfamethoxazole

^a Enterococcus spp. with an intrinsic resistance